Citigroup’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.37M | Sell |
18,000
-12,000
| -40% | -$1.59M | ﹤0.01% | 2561 |
|
|
2025
Q4 | $4.25M | Buy |
+30,000
| New | +$4.35M | ﹤0.01% | 2139 |
|
|
2025
Q2 | – | Sell |
-57,000
| Closed | -$6.3M | – | 5821 |
|
|
2025
Q1 | $6.3M | Buy |
57,000
+30,000
| +111% | +$3.8M | ﹤0.01% | 1700 |
|
|
2024
Q4 | $3.69M | Sell |
27,000
-32,500
| -55% | -$4.02M | ﹤0.01% | 2260 |
|
|
2024
Q3 | $6.86M | Buy |
+59,500
| New | +$8.16M | ﹤0.01% | 1591 |
|
|
2024
Q2 | – | Sell |
-30,000
| Closed | -$4.14M | – | 5715 |
|
|
2024
Q1 | $4.14M | Hold |
30,000
| – | – | ﹤0.01% | 1850 |
|
|
2023
Q4 | $3.95M | Buy |
+30,000
| New | +$3.45M | ﹤0.01% | 1749 |
|
|
2023
Q3 | – | Sell |
-60,000
| Closed | -$5.66M | – | 5748 |
|
|
2023
Q2 | $5.66M | Buy |
60,000
+30,000
| +100% | +$2.93M | ﹤0.01% | 1424 |
|
|
2023
Q1 | $3.04M | Buy |
+30,000
| New | +$3.12M | ﹤0.01% | 1756 |
|
|
2022
Q4 | – | Sell |
-19,000
| Closed | -$2.02M | – | 5894 |
|
|
2022
Q3 | $2.02M | Buy |
+19,000
| New | +$1.93M | ﹤0.01% | 2130 |
|
|
2021
Q1 | – | Sell |
-14,300
| Closed | -$1.37M | – | 7008 |
|
|
2020
Q4 | $1.37M | Sell |
14,300
-64,000
| -82% | -$6.18M | ﹤0.01% | 3233 |
|
|
2020
Q3 | $7.53M | Buy |
78,300
+8,000
| +11% | +$925K | ﹤0.01% | 1603 |
|
|
2020
Q2 | $8.58M | Buy |
70,300
+36,100
| +106% | +$3.99M | 0.01% | 1419 |
|
|
2020
Q1 | $2.96M | Buy |
34,200
+2,800
| +9% | +$274K | ﹤0.01% | 2119 |
|
|
2019
Q4 | $3.38M | Sell |
31,400
-2,500
| -7% | -$262K | ﹤0.01% | 2399 |
|
|
2019
Q3 | $3.06M | Sell |
33,900
-5,400
| -14% | -$505K | ﹤0.01% | 2396 |
|
|
2019
Q2 | $3.32M | Buy |
39,300
+6,400
| +19% | +$525K | ﹤0.01% | 2320 |
|
|
2019
Q1 | $2.9M | Sell |
32,900
-38,600
| -54% | -$3.23M | ﹤0.01% | 2258 |
|
|
2018
Q4 | $5.11M | Buy |
71,500
+60,400
| +544% | +$5.79M | 0.01% | 1791 |
|
|
2018
Q3 | $1.36M | Buy |
11,100
+5,300
| +91% | +$601K | ﹤0.01% | 3142 |
|
|
2018
Q2 | $570K | Sell |
5,800
-5,000
| -46% | -$448K | ﹤0.01% | 3953 |
|
|
2018
Q1 | $895K | Buy |
10,800
+8,200
| +315% | +$692K | ﹤0.01% | 3349 |
|
|
2017
Q4 | $202K | Sell |
2,600
-37,000
| -93% | -$2.52M | ﹤0.01% | 5026 |
|
|
2017
Q3 | $2.43M | Sell |
39,600
-3,100
| -7% | -$164K | ﹤0.01% | 2453 |
|
|
2017
Q2 | $1.96M | Buy |
42,700
+41,700
| +4,170% | +$2.02M | ﹤0.01% | 2614 |
|
|
2017
Q1 | $43K | Buy |
1,000
+800
| +400% | +$34.3K | ﹤0.01% | 5795 |
|
|
2016
Q4 | $8K | Sell |
200
-300
| -60% | -$13.6K | ﹤0.01% | 6805 |
|
|
2016
Q3 | $25K | Hold |
500
| – | – | ﹤0.01% | 6089 |
|
|
2016
Q2 | $23K | Buy |
500
+300
| +150% | +$13.8K | ﹤0.01% | 6068 |
|
|
2016
Q1 | $8K | Sell |
200
-2,100
| -91% | -$83.3K | ﹤0.01% | 6866 |
|
|
2015
Q4 | $130K | Buy |
2,300
+1,000
| +77% | +$50.8K | ﹤0.01% | 5132 |
|
|
2015
Q3 | $52K | Buy |
+1,300
| New | +$62.8K | ﹤0.01% | 5409 |
|
Other funds holding NBIX
VPM
VCM
Citigroup's NBIX Position: Q1 2026 in Review
Citigroup increased its Neurocrine Biosciences (NBIX) stake by 8.9% in Q1 2026, buying an estimated $1.22M and bringing the position to 112,442 shares worth $14.8M. The position accounts for 0.01% of the portfolio, ranked #1241.
Citigroup first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $51.6M in Q1 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Citigroup held 112,442 shares of Neurocrine Biosciences worth $14.8M as of Q1 2026.
- Citigroup bought 9,169 Neurocrine Biosciences shares in Q1 2026, an estimated $1.22M.
- Neurocrine Biosciences made up 0.01% of Citigroup's portfolio in Q1 2026, its #1241 holding.
- Citigroup first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Neurocrine Biosciences position peaked at $51.6M in Q1 2025.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.